Prion Protein

Migration, Crosslink

📖

Prion Protein

active

wiki page Created: 2026-04-02T07:19:12 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-prnp-protein

📖 Wiki Page

protein3290 wordssynced 2026-04-02

Prion Protein (PRNP)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Prion Protein</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>PRNP</td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Major prion protein (PrP^c)</td>
</tr>
<tr>
<td class="label">Alternative Names</td>
<td>PrP27-30, PrP33-35, CD230</td>
</tr>
<tr>
<td class="label">HGNC ID</td>
<td>HGNC:9444</td>
</tr>
<tr>
<td class="label">Entrez Gene ID</td>
<td>5622</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P04156</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>20p13</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>253 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~33-35 kDa (unglycosylated)</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Sporadic CJD</td>
<td>Sporadic</td>
</tr>
<tr>
<td class="label">Genetic CJD</td>
<td>Genetic</td>
</tr>
<tr>
<td class="label">Variant CJD</td>
<td>Acquired</td>
</tr>
<tr>
<td class="label">Fatal Familial Insomnia</td>
<td>Genetic</td>
</tr>
<tr>
<td class="label">GSS Syndrome</td>
<td>Genetic</td>
</tr>
<tr>
<td class="label">Kuru</td>
<td>Acquired</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Species</td>
</tr>
<tr>
<td class="label">Scrapie</td>
<td>Sheep/Goats</td>

...

Prion Protein (PRNP)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Prion Protein</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>PRNP</td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Major prion protein (PrP^c)</td>
</tr>
<tr>
<td class="label">Alternative Names</td>
<td>PrP27-30, PrP33-35, CD230</td>
</tr>
<tr>
<td class="label">HGNC ID</td>
<td>HGNC:9444</td>
</tr>
<tr>
<td class="label">Entrez Gene ID</td>
<td>5622</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P04156</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>20p13</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>253 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~33-35 kDa (unglycosylated)</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Sporadic CJD</td>
<td>Sporadic</td>
</tr>
<tr>
<td class="label">Genetic CJD</td>
<td>Genetic</td>
</tr>
<tr>
<td class="label">Variant CJD</td>
<td>Acquired</td>
</tr>
<tr>
<td class="label">Fatal Familial Insomnia</td>
<td>Genetic</td>
</tr>
<tr>
<td class="label">GSS Syndrome</td>
<td>Genetic</td>
</tr>
<tr>
<td class="label">Kuru</td>
<td>Acquired</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Species</td>
</tr>
<tr>
<td class="label">Scrapie</td>
<td>Sheep/Goats</td>
</tr>
<tr>
<td class="label">BSE</td>
<td>Cattle</td>
</tr>
<tr>
<td class="label">Chronic Wasting Disease</td>
<td>Deer/Elk</td>
</tr>
<tr>
<td class="label">FSE</td>
<td>Cats</td>
</tr>
<tr>
<td class="label">TME</td>
<td>Mink</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">6 edges</a></td>
</tr>
</table>

Introduction

The prion protein (PrP) represents one of the most fascinating and enigmatic molecules in neurobiology. Encoded by the PRNP gene, this GPI-anchored protein is central to a unique group of neurodegenerative diseases known as transmissible spongiform encephalopathies (TSEs) or prion diseases. Unlike other protein aggregation disorders, prions possess the remarkable ability to transmit their abnormal conformation to normal cellular proteins, creating a self-propagating chain reaction that leads to rapid neurodegeneration. This page provides comprehensive coverage of prion protein structure, function, mechanisms of pathogenesis, disease associations, and therapeutic approaches [@prusiner2023][@aguzzi2009].

Overview

The prion protein (PrP), encoded by the PRNP gene located on chromosome 20p13, is a glycosylphosphatidylinositol (GPI)-anchored protein that plays a central role in prion diseases. Prions are unique among pathogenic agents in that they consist entirely of misfolded protein and lack any nucleic acid component. The normal cellular isoform (PrP^c) is expressed predominantly in the central nervous system but also in peripheral tissues including lymphocytes, cardiomyocytes, and gastrointestinal epithelial cells. The disease-associated scrapie isoform (PrP^Sc) differs from PrP^c primarily in its conformational state, adopting a higher β-sheet content that renders it resistant to proteolysis and capable of forming insoluble aggregates [@caughey2003][@cohen1998].

Prion diseases affect both humans and animals, with manifestations ranging from rapid progressive dementia to cerebellar ataxia. Human prion diseases include Creutzfeldt-Jakob disease (CJD) in its sporadic, familial, and acquired forms, variant CJD (vCJD), fatal familial insomnia (FFI), Gerstmann-Sträussler-Scheinker syndrome (GSS), and kuru. Animal prion diseases include scrapie in sheep and goats, bovine spongiform encephalopathy (BSE), and chronic wasting disease (CWD) in cervids [@collinge2001][@wadsworth2007].

Protein Information

Protein Structure

Domain Architecture

The prion protein contains several distinct structural domains that serve different functions:

N-terminal signal peptide (residues 1-23): Targets the protein to the secretory pathway and is cleaved during post-translational processing

Octarepeat region (residues 51-91): Contains five tandem octapeptide repeats that bind copper ions (Cu^2+) with high affinity

Central hydrophobic region (residues 106-126): Known as the "hydrophobic core," this region is critical for prion formation and contains the sites of several pathogenic mutations

C-terminal globular domain (residues 121-231): Contains the three α-helices and two β-strands that define the protein's tertiary structure

GPI anchor signal sequence (residues 232-253): Directs GPI anchor attachment for membrane localization

Three-Dimensional Structure

The cellular prion protein (PrP^c) adopts a well-defined three-dimensional structure:

α-helices: Three α-helices are located at residues 144-154 (Helix A), 173-194 (Helix B), and 200-228 (Helix C)
β-sheets: Two β-strands at residues 128-131 (β1) and 161-164 (β2) form a small β-sheet
Disulfide bond: A highly conserved disulfide bond connects Helix B and Helix C (Cys179-Cys214)
Copper binding sites: The octarepeat region coordinates copper ions through histidine residues at positions 69, 76, 84, and 91
N-linked glycans: Two N-linked glycosylation sites at Asn181 and Asn197

The conversion from PrP^c to PrP^Sc involves a dramatic conformational rearrangement characterized by:

Loss of α-helical content (from ~40% to less than 10%)
Increase in β-sheet structure (from less than 10% to over 40%)
Formation of amyloid fibrils with cross-β structure
Increased resistance to proteolytic digestion

Prion Strains

One of the most remarkable properties of prions is strain diversity. Multiple distinct disease phenotypes can arise from the same amino acid sequence of PrP. This strain diversity is encoded in the three-dimensional conformation of PrP^Sc, which differs between strains despite identical primary sequences. Strain differences manifest as:

Variable incubation periods
Different neuropathological patterns
Distinct clinical presentations
Differential patterns of protease resistance
Species-specific transmission barriers

The mechanism of strain propagation involves the templated conversion of PrP^c adopting the specific conformational template of the infecting PrP^Sc strain [@caughey2018][@soto2011].

Normal Cellular Function (PrP^c)

Despite extensive research, the normal physiological function of PrP^c remains incompletely understood. However, multiple lines of evidence support several important roles:

Synaptic Function and Neuronal Signaling

PrP^c is highly enriched at synaptic terminals, particularly in the presynaptic compartment. Studies using Prnp^0/0 mice (PRNP knockout) have revealed:

Altered synaptic transmission with impaired long-term potentiation (LTP)
Reduced neurotransmitter release efficiency
Abnormalities in synaptic vesicle cycling
Defects in GABAergic signaling

PrP^c interacts with various synaptic proteins including:

Synapsin I
Grb2 and other adaptor proteins
Neuronal nitric oxide synthase (nNOS)
Lipid rafts at synaptic membranes

Copper Ion Homeostasis

The octarepeat region of PrP^c binds copper ions (Cu^2+) with high affinity and may function as a copper buffer or sensor. Copper binding is thought to:

Modulate PrP^c endocytosis and trafficking
Influence antioxidant enzyme activity
Regulate copper uptake at the synapse
Protect against oxidative stress

The relationship between copper and prion disease is complex, as both deficiency and excess of copper can influence disease progression in different contexts [@brown2009].

Neuroprotection and Cell Survival

PrP^c possesses intrinsic neuroprotective properties:

Anti-apoptotic activity through inhibition of Bax-mediated cell death
Antioxidant properties via copper-zinc superoxide dismutase (SOD1) activation
Protection against oxidative stress-induced neuronal damage
Regulation of autophagy and cellular clearance pathways

Myelin Maintenance and Oligodendrocyte Function

PrP^c is expressed in oligodendrocytes and myelin-producing cells. Studies indicate:

PrP^c deficiency leads to subtle myelin abnormalities
Impaired oligodendrocyte maturation in knockout models
Potential role in maintaining myelin integrity

Cell Adhesion and Signaling

PrP^c interacts with various cell surface molecules and may function as:

A signaling receptor or co-receptor
A cell adhesion molecule
A platform for assembling signaling complexes

Disease Mechanisms (PrP^Sc)

The conversion of normal PrP^c to the disease-associated PrP^Sc isoform initiates a cascade of pathological events:

Conformational Conversion

The templated conversion of PrP^c to PrP^Sc involves:

Direct interaction between PrP^c and PrP^Sc

Structural rearrangement templated by PrP^Sc

Release of newly converted PrP^Sc

Propagation of the conversion cycle

The efficiency of this conversion is influenced by:

PrP sequence (species-specific differences)
PrP expression levels
Cellular factors and chaperones
Membrane environment and lipid composition

Aggregation and fibril formation

PrP^Sc aggregates manifest as:

Diffuse synaptic deposits
Amyloid plaques (in some disease subtypes)
Spongiform vacuolation
Astrocytic and microglial activation

The aggregation process involves:

Nucleation-dependent polymerization
Formation of oligomeric intermediates
Maturation into amyloid fibrils
Interaction with cellular membranes

Neurotoxicity Mechanisms

Multiple pathways contribute to prion-induced neurodegeneration:

Synaptic dysfunction and loss
Activation of apoptotic pathways (caspase-dependent and independent)
Endoplasmic reticulum stress
Mitochondrial dysfunction
Oxidative stress and lipid peroxidation
Excitotoxicity
[Neuroinflammation](/mechanisms/neuroinflammation)

The "prion toxicity hypothesis" suggests that the intermediate oligomeric species, rather than the mature fibrils, are primarily responsible for neurotoxicity. This concept has therapeutic implications, as targeting these toxic oligomers may be more effective than targeting the end-stage fibrils [@harris2006][@lee2022].

Disease Associations

Human Prion Diseases

Creutzfeldt-Jakob Disease (CJD)

CJD is the most common human prion disease, accounting for approximately 85% of all cases. Three major etiologies are recognized:

Sporadic CJD (sCJD): Accounts for ~85% of cases with no known cause; typically presents with rapidly progressive dementia, ataxia, myoclonus, and characteristic periodic EEG patterns
Genetic CJD (gCJD): Associated with pathogenic mutations in PRNP including E200K, D178N, and V210I; represents ~10-15% of cases
Acquired CJD: Rare, caused by exposure to contaminated tissues (dura mater grafts, growth hormone), or variant CJD from BSE exposure

Variant CJD (vCJD)

Variant CJD emerged in the UK in the 1990s and is causally linked to consumption of BSE-contaminated beef. Key features include:

Younger age of onset (average ~30 years)
Prominent psychiatric and behavioral symptoms at onset
Sensory symptoms and dysesthesias
Later neurological signs including ataxia and dementia
Characteristic "florid" PrP plaques in brain tissue

Fatal Familial Insomnia (FFI)

FFI is caused by the D178N mutation with methionine at position 129. It presents with:

Progressive insomnia and sleep fragmentation
Autonomic dysfunction (hypertension, tachycardia, hyperhidrosis)
Motor disturbances including ataxia and dysarthria
Selective thalamic degeneration
Cognitive decline in later stages

Gerstmann-Sträussler-Scheinker Syndrome (GSS)

GSS is a rare autosomal dominant disorder associated with PRNP mutations (commonly P102L). Features include:

Cerebellar ataxia as the presenting symptom
Slow progression over years to decades
Cognitive decline in later stages
Characteristic amyloid plaque pathology

Animal Prion Diseases

Neurodegenerative Overlap

Prion protein interactions are relevant to other neurodegenerative diseases:

Alzheimer's Disease: PrP^c binds Aβ oligomers and may mediate their synaptic toxicity
Parkinson's Disease: PrP may modulate α-synuclein aggregation and toxicity
Amyotrophic Lateral Sclerosis: PrP expression is altered in motor neurons
Huntington's Disease: PrP interactions with mutant huntingtin

This overlap suggests common mechanisms of protein misfolding and aggregation across neurodegenerative diseases [@rambold2020][@schmitz2020].

Genetic Factors

PRNP Polymorphisms

The polymorphism at codon 129 (methionine vs. valine) profoundly influences prion disease risk:

Homozygosity (M/M or V/V) is overrepresented in sporadic CJD
M/M homozygosity is associated with earlier onset in vCJD
129 genotype influences clinical phenotype and disease duration

PRNP Mutations

Over 40 pathogenic mutations in PRNP cause familial prion diseases:

Pathogenic mutations: P102L (GSS), D178N (FFI/gCJD), E200K (gCJD), V180I (gCJD), M232R (gCJD)
Insertion mutations: Octapeptide repeat insertions cause gCJD
Penetrance: Variable, with some mutations having incomplete penetrance

Diagnostic Approaches

Clinical Diagnosis

Current diagnostic criteria incorporate:

Progressive neurological symptoms
Characteristic neuropsychological profile
Typical neurological signs (myoclonus, ataxia, cortical blindness)
Periodic sharp wave complexes on EEG
Characteristic MRI findings (cortical ribboning, basal ganglia hyperintensities)

Biomarkers

14-3-3 protein in cerebrospinal fluid: High sensitivity for CJD
Total tau: Elevated in CJD vs. other dementias
Neurofilament light chain (NfL): Raised in prion disease
Real-time quaking-induced conversion (RT-QuIC): High specificity for PrP^Sc in CSF

Neuropathology

Characteristic findings include:

Spongiform change (vacuolation)
Neuronal loss
Astrocytic gliosis
PrP deposition (diffuse, synaptic, or plaque-type)
Kuru-type plaques in vCJD

Therapeutic Approaches

Current Status

No disease-modifying therapies exist for prion diseases. Current management is supportive and symptomatic.

Therapeutic Strategies Under Investigation

Anti-prion compounds: Quinacrine, pentosan polysulfate, chlorpromazine

Immunotherapy: Active and passive immunization approaches

Gene silencing: Antisense oligonucleotides (ASOs) targeting PRNP

Protein stabilization: Small molecules stabilizing PrP^c conformation

Copper chelation: Modulating copper-binding dynamics

Aggregation inhibitors: Targeting toxic oligomer formation

Clinical Trials

Multiple Phase I/II trials of quinacrine failed to show efficacy
ASO-based approaches show promise in preclinical models
Immunotherapy trials ongoing but challenging due to blood-brain barrier

Challenges

Rapid disease progression limits therapeutic window
Blood-brain barrier restricts drug delivery
Heterogeneity of prion strains complicates targeting
Lack of validated biomarkers for trial endpoints

Research Models

Animal Models

Prnp knockout mice: Viable with mild neurological phenotypes
Transgenic mice: Expressing mutant human PRNP to model disease
Knock-in mice: Humanized PRNP with disease-causing mutations
Hamster/sheep models: For studying scrapie and BSE

Cell Culture Models

Neuronal cell lines: Overexpressing wild-type or mutant PrP
Induced neurons: From patient-derived iPSCs
Organotypic slice cultures: For studying prion replication

External Links

[NCBI Gene PRNP](https://www.ncbi.nlm.nih.gov/gene/5622)
[UniProt PRNP](https://www.uniprot.org/uniprotkb/P04156)
[OMIM PRNP](https://www.omim.org/entry/176640)
[Prion Watch](http://prion.s3website.com/)
[CJD Foundation](https://cjdfoundation.org/)

Epidemiological Considerations

Global Burden

Prion diseases, while individually rare, represent a significant burden on neurological services worldwide. Sporadic CJD affects approximately 1-2 individuals per million population annually, translating to approximately 7,000-14,000 cases globally each year. The disease typically affects individuals between 50-70 years of age, with no significant gender predilection. The sporadic form accounts for the majority of cases (~85%), while genetic prion diseases represent 10-15%, and acquired forms account for less than 1% of all cases.

Risk Factors and Transmission

The understanding of prion disease transmission has evolved significantly over the past three decades. Key transmission routes include:

Dietary exposure: Consumption of BSE-contaminated beef products led to the vCJD epidemic in the UK
Iatrogenic transmission: Cases documented from contaminated dura mater grafts, human growth hormone, and corneal transplants
Blood transfusion: Four cases of vCJD transmission via blood transfusion have been documented
Genetic susceptibility: Homozygosity at codon 129 and specific PRNP mutations increase susceptibility

The demonstration of asymptomatic carrier states, particularly for vCJD, has raised concerns about potential secondary transmission through medical procedures and blood products. Estimated prevalence of asymptomatic vCJD infection in the UK population is approximately 1 in 2,000, based on tonsillectomy studies [@geschwind2015].

Population Genetics

The PRNP gene shows evidence of balancing selection in human populations, suggesting that prion protein may have provided a selective advantage during evolution. The codon 129 polymorphism represents a classic example of frequency-dependent selection, with both methionine and valine alleles maintained at significant frequencies in all populations studied. This polymorphism may have conferred differential resistance to past prion disease epidemics or other infectious agents.

Molecular Mechanisms of PrP^c to PrP^Sc Conversion

Nucleation-Dependent Polymerization

The conversion of PrP^c to PrP^Sc follows a nucleation-dependent polymerization model:

Lag phase: Stochastic formation of metastable oligomers

Nucleation: Critical oligomers become stable "seeds"

Growth phase: Seeds catalyze conversion of additional PrP^c molecules

Stationary phase: Equilibrium between monomers and polymers

This model explains the long incubation periods in some prion diseases and the observation that disease can be triggered by exposure to pre-formed PrP^Sc seeds.

Template-Directed Misfolding

The conformational conversion involves transfer of structural information from PrP^Sc to PrP^c:

The β-sheet-rich PrP^Sc template stabilizes similar structures in PrP^c
Specific interactions between PrP^Sc and PrP^c involve the central region
Post-translational modifications influence conversion efficiency
Membrane association may facilitate conversion through lipid interactions

Species Barriers

Transmission between species is typically inefficient due to sequence differences between PrP proteins. The species barrier concept explains:

Differences in amino acid sequence at key positions
Conformation compatibility between donor PrP^Sc and host PrP^c
Requirement for specific structural complementarity

Transgenic mice expressing foreign PrP sequences have demonstrated that species barriers can be overcome through genetic manipulation, confirming the central role of PrP sequence in determining transmission efficiency [@zerr2020][@kunze2022].

Cellular Biology of Prion Diseases

Cellular Entry and Spread

Prion replication occurs primarily within the central nervous system, but initial entry involves:

Peripheral replication in lymphoid tissues
Migration via peripheral nerves
Retrograde transport to the spinal cord
Subsequent spread throughout the brain

The precise mechanisms of cellular entry and spread remain an area of active investigation, with roles proposed for:

Cell surface PrP^c interactions
Receptor-mediated endocytosis
Tunneling nanotubes between cells
Extracellular vesicle trafficking

Glial Responses

Prion disease is characterized by prominent astrocytic and microglial activation:

Reactive astrocytes produce inflammatory cytokines
Microglial activation accompanies neuronal loss
Both cell types may contribute to neurotoxicity
Gliosis correlates with disease progression

Neuroinflammation

Chronic neuroinflammation is a hallmark of prion disease:

Elevated cytokines including IL-1β, IL-6, TNF-α
Complement system activation
Prostaglandin production
Potential contribution to disease progression

Prevention and Public Health Measures

Infection Control

Standard sterilization procedures are ineffective against prions. Recommended measures include:

Autoclaving at 134°C for 18+ minutes
Sodium hydroxide (1N) treatment for 1 hour
Enhanced precautions for high-risk tissues
Single-use instruments where possible

Blood Safety

Blood donor deferral policies have been implemented in multiple countries for individuals at risk of vCJD. Pathogen reduction technologies are being developed to inactivate prions in blood products.

Food Safety

BSE surveillance and feed restrictions have dramatically reduced the risk of dietary prion exposure. The experience with the BSE epidemic led to significant changes in food safety regulations worldwide.

Future Directions

Biomarker Development

Reliable biomarkers for early diagnosis and treatment monitoring remain a high priority:

Blood-based tests for PrP^Sc detection
Neurofilament light chain as a progression marker
Imaging biomarkers for prion deposition
Genetic risk stratification

Therapeutic Development

Several promising approaches are advancing through preclinical and early clinical development:

ASO-mediated PRNP knock-down showing efficacy in mouse models
Anti-prion antibodies in development for passive immunization
Small molecule aggregation inhibitors entering clinical trials
Gene therapy approaches using viral vectors

Understanding Strain Diversity

Advances in strain typing and characterization will enable:

Better understanding of genotype-phenotype relationships
Improved diagnostic specificity
Development of strain-targeted therapeutics
Better assessment of transmission risks

Conclusion

The prion protein represents a fascinating example of how a single protein can have dramatically different biological properties depending on its conformational state. The study of prion diseases has revealed fundamental principles of protein misfolding, aggregation, and neurotoxicity that apply broadly to neurodegenerative diseases. While significant challenges remain in developing effective therapies, ongoing research continues to advance our understanding of prion biology and disease mechanisms. The development of biomarkers, therapeutic agents, and preventive strategies offers hope for affected individuals and families.

Additional References

[Collins SJ et al., Epidemiology of CJD (2022)](https://pubmed.ncbi.nlm.nih.gov/34778901/)

[Hill AF & Collinge J, Prion strains and disease phenotypes (2003)](https://pubmed.ncbi.nlm.nih.gov/14578620/)

[Miller MW & CWD in cervids (2020)](https://pubmed.ncbi.nlm.nih.gov/32268422/)

[Brandner S & Jaunmuktane Z, Prion disease pathology (2022)](https://pubmed.ncbi.nlm.nih.gov/35489447/)

References

[Unknown, Prusiner SB, Prion Biology and Diseases (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37254267/)

[Unknown, Aguzzi A & Calella AM, Prions: protein aggregation and beyond (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/19543732/)

[Unknown, Caughey B & Lansbury PT, Protofibrils, pores, fibrils, and neurodegeneration (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/12730368/)

[Unknown, Cohen FE & Prusiner SB, Structural studies of prion proteins (1998) (1998)](https://pubmed.ncbi.nlm.nih.gov/9771754/)

[Unknown, Collinge J, Prion diseases of humans and animals (2001) (2001)](https://pubmed.ncbi.nlm.nih.gov/11255527/)

[Unknown, Wadsworth JDF & Collinge J, Update on human prion disease (2007) (2007)](https://pubmed.ncbi.nlm.nih.gov/17540367/)

[Caughey B et al., Prion protein biology (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29976769/)

[Unknown, Soto C & Castilla J, The dam from prion diseases (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21827944/)

[Unknown, Brown DR, The prion protein query (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/19399618/)

[Unknown, Harris DA & True HL, New insights into prion structure and toxicity (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/17062768/)

[Lee S et al., Neurotoxicity of prion protein (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35604485/)

[Rambold AS et al., Linking prion protein to neurodegeneration (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32360412/)

[Schmitz M et al., Prion diseases and Alzheimer's disease overlap (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32449512/)

[Unknown, Geschwind MD, Prion diseases (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26052946/)

[Unknown, Zerr I & Hermann P, Diagnostic challenges in CJD (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32070203/)

[Kunze B et al., Antisense therapy for prion disease (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35093418/)

[Miyajima Y et al., Prion protein and copper binding (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34411245/)

[Soto C et al., Prion conversion and aggregation (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32520674/)

[Watzlawik J et al., Prion strains and species barriers (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33626658/)

[Unknown, Scheckel C & Aguzzi A, Prion pathogenesis and therapeutic strategies (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32015018/)

Pathway Diagram

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

PRNPPROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-prnp-protein
kg_node_id	PRNPPROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-fdf0600751e5
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-prnp-protein'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

32

Outgoing

18

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Prion Protein

Prion Protein (PRNP)

Prion Protein (PRNP)

Introduction

Overview

Protein Information

Protein Structure

Domain Architecture

Three-Dimensional Structure

Prion Strains

Normal Cellular Function (PrP^c)

Synaptic Function and Neuronal Signaling

Copper Ion Homeostasis

Neuroprotection and Cell Survival

Myelin Maintenance and Oligodendrocyte Function

Cell Adhesion and Signaling

Disease Mechanisms (PrP^Sc)

Conformational Conversion

Aggregation and fibril formation

Neurotoxicity Mechanisms

Disease Associations

Human Prion Diseases

Creutzfeldt-Jakob Disease (CJD)

Variant CJD (vCJD)

Fatal Familial Insomnia (FFI)

Gerstmann-Sträussler-Scheinker Syndrome (GSS)

Animal Prion Diseases

Neurodegenerative Overlap

Genetic Factors

PRNP Polymorphisms

PRNP Mutations

Diagnostic Approaches

Clinical Diagnosis

Biomarkers

Neuropathology

Therapeutic Approaches

Current Status

Therapeutic Strategies Under Investigation

Clinical Trials

Challenges

Research Models

Animal Models

Cell Culture Models

See Also

External Links

Epidemiological Considerations

Global Burden

Risk Factors and Transmission

Population Genetics

Molecular Mechanisms of PrP^c to PrP^Sc Conversion

Nucleation-Dependent Polymerization

Template-Directed Misfolding

Species Barriers

Cellular Biology of Prion Diseases

Cellular Entry and Spread

Glial Responses

Neuroinflammation

Prevention and Public Health Measures

Infection Control

Blood Safety

Food Safety

Future Directions

Biomarker Development

Therapeutic Development

Understanding Strain Diversity

Conclusion

Additional References

References

Pathway Diagram

💬 Discussion